دورية أكاديمية
Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response.
| العنوان: | Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response. |
|---|---|
| المؤلفون: | Asangba AE; Department of Surgery, Mayo Clinic, Rochester, MN, USA. asangba.abigail@mayo.edu.; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA. asangba.abigail@mayo.edu., Chen J; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Goergen KM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Larson MC; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Oberg AL; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Casarin J; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA., Multinu F; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.; IEO, European Institute of Oncology IRCCS, Milan, Italy., Kaufmann SH; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Mariani A; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA., Chia N; Department of Surgery, Mayo Clinic, Rochester, MN, USA.; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA., Walther-Antonio MRS; Department of Surgery, Mayo Clinic, Rochester, MN, USA.; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA. |
| المصدر: | Scientific reports [Sci Rep] 2023 Jan 13; Vol. 13 (1), pp. 730. Date of Electronic Publication: 2023 Jan 13. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
| مواضيع طبية MeSH: | Ovarian Neoplasms*/diagnosis , Ovarian Neoplasms*/therapy , Ovarian Neoplasms*/pathology , Microbiota*, Humans ; Female ; Prognosis ; Early Detection of Cancer |
| مستخلص: | Ovarian cancer (OC) is the second most common gynecological malignancy and the fifth leading cause of death due to cancer in women in the United States mainly due to the late-stage diagnosis of this cancer. It is, therefore, critical to identify potential indicators to aid in early detection and diagnosis of this disease. We investigated the microbiome associated with OC and its potential role in detection, progression as well as prognosis of the disease. We identified a distinct OC microbiome with general enrichment of several microbial taxa, including Dialister, Corynebacterium, Prevotella, and Peptoniphilus in the OC cohort in all body sites excluding stool and omentum which were not sampled from the benign cohort. These taxa were, however, depleted in the advanced-stage and high-grade OC patients compared to early-stage and low-grade OC patients suggestive of decrease accumulation in advanced disease and could serve as potential indicators for early detection of OC. Similarly, we also observed the accumulation of these mainly pathogenic taxa in OC patients with adverse treatment outcomes compared to those without events and could also serve as potential indicators for predicting patients' responses to treatment. These findings provide important insights into the potential use of the microbiome as indicators in (1) early detection of and screening for OC and (2) predicting patients' response to treatment. Given the limited number of patients enrolled in the study, these results would need to be further investigated and confirmed in a larger study. (© 2023. The Author(s).) |
| References: | Am J Epidemiol. 1992 Nov 15;136(10):1184-203. (PMID: 1476141) Cancer. 2019 Dec 15;125 Suppl 24:4598-4601. (PMID: 31967681) Trends Cancer. 2020 Apr;6(4):277-287. (PMID: 32209443) Nat Rev Dis Primers. 2016 Aug 25;2:16061. (PMID: 27558151) Virol J. 2013 Nov 20;10:343. (PMID: 24252426) Open Forum Infect Dis. 2017 Jan 09;4(1):ofw272. (PMID: 28480264) Nat Commun. 2020 Sep 24;11(1):4822. (PMID: 32973149) J Clin Microbiol. 2012 Aug;50(8):2561-7. (PMID: 22593594) J Clin Oncol. 2016 Aug 20;34(24):2888-98. (PMID: 27325851) Sci Rep. 2019 Dec 16;9(1):19213. (PMID: 31844128) Br J Cancer. 2003 Aug 18;89(4):672-5. (PMID: 12915876) Genome Res. 2012 Feb;22(2):292-8. (PMID: 22009990) Nat Biotechnol. 2019 Aug;37(8):852-857. (PMID: 31341288) Am J Pathol. 2004 May;164(5):1511-8. (PMID: 15111296) N Engl J Med. 2007 Oct 18;357(16):1579-88. (PMID: 17942871) Nat Biotechnol. 2016 Sep;34(9):942-9. (PMID: 27454739) Clin Cancer Res. 2019 Oct 15;25(20):6170-6179. (PMID: 31358543) Cell. 2019 Aug 8;178(4):795-806.e12. (PMID: 31398337) Appl Environ Microbiol. 2004 Aug;70(8):4800-6. (PMID: 15294817) Cancer Causes Control. 2020 Jan;31(1):25-31. (PMID: 31673820) Gut Pathog. 2021 Jan 12;13(1):2. (PMID: 33436075) Technol Cancer Res Treat. 2019 Jan 1;18:1533033819867354. (PMID: 31370775) J Clin Microbiol. 2012 Oct;50(10):3152-8. (PMID: 22837327) Nat Commun. 2020 Oct 5;11(1):4982. (PMID: 33020474) Clin Infect Dis. 2002 Dec 1;35(11):1434-40. (PMID: 12439810) Front Microbiol. 2017 Jun 30;8:1226. (PMID: 28713353) Nat Methods. 2016 Jul;13(7):581-3. (PMID: 27214047) Front Microbiol. 2018 May 15;9:951. (PMID: 29867857) BMC Urol. 2020 Dec 7;20(1):192. (PMID: 33287796) Genome Med. 2016 Nov 25;8(1):122. (PMID: 27884207) CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402) Gynecol Oncol. 2015 Sep;138(3):741-9. (PMID: 26080287) Sci Rep. 2018 Aug 14;8(1):12157. (PMID: 30108246) Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6. (PMID: 23193283) Sci Rep. 2021 Jan 25;11(1):2156. (PMID: 33495564) Science. 2020 May 29;368(6494):973-980. (PMID: 32467386) Sex Transm Dis. 2008 Jun;35(6):611-3. (PMID: 18418301) Nutr Diabetes. 2015 Jun 15;5:e159. (PMID: 26075636) Gynecol Oncol. 2008 Mar;108(3):641-51. (PMID: 18221779) Lancet Oncol. 2019 Aug;20(8):1171-1182. (PMID: 31300207) Genome Biol. 2022 Apr 14;23(1):95. (PMID: 35421994) Mol Med. 2021 Apr 1;27(1):33. (PMID: 33794773) Am J Respir Crit Care Med. 2018 Nov 1;198(9):1188-1198. (PMID: 29864375) J Infect Dis. 2019 Aug 30;220(7):1099-1108. (PMID: 30715405) Open Microbiol J. 2016 Mar 10;10:27-31. (PMID: 27014376) Am J Epidemiol. 1990 Sep;132(3):446-52. (PMID: 2389749) Bioinformatics. 2012 Aug 15;28(16):2106-13. (PMID: 22711789) Gut Microbes. 2021 Jan-Dec;13(1):1-21. (PMID: 33525961) Antimicrob Agents Chemother. 2007 Dec;51(12):4498-501. (PMID: 17923492) Appl Environ Microbiol. 2005 Dec;71(12):8228-35. (PMID: 16332807) PeerJ. 2021 Jun 17;9:e11574. (PMID: 34178459) Cancer Discov. 2015 Nov;5(11):1137-54. (PMID: 26463832) Lancet. 2015 May 9;385(9980):1835-42. (PMID: 25684585) J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706. (PMID: 17148771) Front Microbiol. 2021 Jul 23;12:674835. (PMID: 34367083) N Engl J Med. 1991 Oct 17;325(16):1132-6. (PMID: 1891021) Nat Med. 2009 Sep;15(9):1016-22. (PMID: 19701202) J Obstet Gynaecol Res. 2021 Apr;47(4):1527-1535. (PMID: 33506580) J Microbiol Immunol Infect. 2016 Oct;49(5):804-808. (PMID: 25066704) Science. 2017 Sep 15;357(6356):1156-1160. (PMID: 28912244) |
| معلومات مُعتمدة: | KL2 TR002379 United States TR NCATS NIH HHS; P30 CA015083 United States CA NCI NIH HHS; P50 CA136393 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20230113 Date Completed: 20230117 Latest Revision: 20240717 |
| رمز التحديث: | 20240717 |
| مُعرف محوري في PubMed: | PMC9839674 |
| DOI: | 10.1038/s41598-023-27555-x |
| PMID: | 36639731 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2045-2322 |
|---|---|
| DOI: | 10.1038/s41598-023-27555-x |